Ireland – Laboratory, optical and precision equipments (excl. glasses) – Contract award notice for the provision of a suitable designated benchtop platform for Neurodegeneration Biomarker identification

Following a Pre Market Consultation ( Etenders Resource ID 6396922 ) to identify suitable suppliers that can meet the Hospitals requirements it was determined that only Fujirebio Europe N.V that can meet St James’s Hospitals mandatory and desirable criteria . St James’s Hospital have a requirement to change from current (ELISA) platform for analysis of Neurodegeneration Biomarker Identification and have decided to engage with Fujirebio NV for the provision of their LUMIPULSE G600II, a chemiluminescent enzyme immunoassay (CLEIA) benchtop analyzer